Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Insulet forecasts total company revenue growth of 16%-20% for 2025, with Omnipod revenue growth projected at 17%-21%. U.S. Omnipod revenue is expected to grow 16%-20%, driven by the continued ramp-up ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Insulet (PODD – Research Report) today and set a price target of $293.00.

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Raymond James analyst Jayson Bedford raised the firm’s price target on Insulet (PODD) to $328 from $294 and keeps an Outperform rating on the ...

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics ...

Van ECK Associates Corp lessened its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 2.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.